EUVIMEDEUVIMED entdecken
Crossref

Changes in the frequency of postoperative 131I therapy and longitudinal assessment of psychological status and quality of life in patients with differentiated thyroid cancer

Yibo Chen, Xiaoya Guo, Jieqiong Shao, Lixiang Wu, Meiling Kang, Mofan Liu, Yuehao Xia, Zhifang Wu, Sijin Li, Keyi Lu

Supportive Care in Cancer · 2026-04 · 34 (4)

DOI: 10.1007/s00520-026-10474-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 06.03.2026. Verfasst von Yibo Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Quality of Life, Iodine Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic Research Program of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aims to analyze the annual trends in postoperative 131I treatment frequency among differentiated thyroid cancer (DTC) patients and systematically evaluate the changes in psychological status and quality of life across different treatment stages, thereby providing an evidence-based foundation for developing precise patient support strategies. METHODS: We conducted a retrospective analysis of 1651 patients with nondistant metastatic DTC treated between 2018 and 2023 to examine trends in 131I therapy. In addition, an observational analysis of routinely collected questionnaire data from 2024 was performed, including a psychological stress scale, the Hospital Anxiety and Depression Scale (HADS), and the Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), to assess patients' psychological status and quality of life as part of standard clinical follow-up across different treatment stages. RESULTS: The adoption of single-dose 131I therapy for nonmetastatic DTC rose markedly from 5.99% (2018) to 98.34% (2023) (χ2 = 87.407, p < 0.05), surpassing 92% after 2020. This shift was accompanied by a 38.9% reduction in treatment-cycle psychological distress (p < 0.001), though acceptance decreased by 6.6% at the 6-12-month assessment stage (p = 0.028). Willingness for multiple therapies declined 28.1% (p < 0.05), with variations by sex, education, and physician. HADS scores improved at subsequent assessment stages, and baseline anxiety was significantly associated with increased psychological risk at later stages (r = 0.534). Quality of life initially declined but showed subsequent improvement across treatment stages (p < 0.01). CONCLUSION: Under the trend of single-session 131I therapy, a phase-specific health education system for high-risk groups is suggested. It may help strengthen pre-treatment cognitive intervention and post-treatment psychological support and provide a theoretical reference for improving adherence and long-term quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsQuality of LifeIodine RadioisotopesHumansFemaleMiddle AgedMaleRetrospective StudiesAdultLongitudinal StudiesAgedSurveys and QuestionnairesAnxietyDepressionStress, PsychologicalPostoperative PeriodThyroidectomy

Stichwörter der Autor:innen

Anxiety and depressionDifferentiated thyroid cancerIodine radioisotopesPsychological conditionQuality of lifeTreatment trends

Substanzen

Iodine RadioisotopesIodine-131

Autor:innen und Institutionen

  • Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
  • Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
  • Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
  • Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan, People's Republic of China, Shanxi.
  • CAEA Center of Excellence on Nuclear Technology Applications for the Diagnosis, Treatment & Transformation of Nuclear Medicine, Shanxi, Taiyuan, People's Republic of China.
  • Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. lisjnm123@163.com.

Förderung

  • Basic Research Program of Shanxi Province

Zitieren

APA

Chen, Y., Guo, X., Shao, J., Wu, L., Kang, M., Liu, M., Xia, Y., Wu, Z., Li, S., & Lu, K. (2026). Changes in the frequency of postoperative 131I therapy and longitudinal assessment of psychological status and quality of life in patients with differentiated thyroid cancer. Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10474-8

Vancouver

Chen Y, Guo X, Shao J, Wu L, Kang M, Liu M, et al. Changes in the frequency of postoperative 131I therapy and longitudinal assessment of psychological status and quality of life in patients with differentiated thyroid cancer. Supportive Care in Cancer. 2026;34(4). doi:10.1007/s00520-026-10474-8

BibTeX
@article{Chen2026,
  author = {Chen, Yibo and Guo, Xiaoya and Shao, Jieqiong and Wu, Lixiang and Kang, Meiling and Liu, Mofan and Xia, Yuehao and Wu, Zhifang and Li, Sijin and Lu, Keyi},
  title = {Changes in the frequency of postoperative 131I therapy and longitudinal assessment of psychological status and quality of life in patients with differentiated thyroid cancer},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {4},
  doi = {10.1007/s00520-026-10474-8}
}
Kostenlos starten →